Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
Cancer Res Treat. 2015;47(2):266-273.   Published online 2014 Aug 29     DOI: https://doi.org/10.4143/crt.2013.158
Citations to this article as recorded by Crossref logo
A Systematic Study of Novel Drug Delivery Mechanisms and Treatment Strategies for Pancreatic Cancer
Umme Hani, Riyaz Ali M. Osmani, Ayesha Siddiqua, Shadma Wahab, Sadia Batool, Hissana Ather, Norhan Shereba, Ali Alqahtani
Journal of Drug Delivery Science and Technology.2021; : 102539.     CrossRef
Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer
Kunxi Bao, Xiaobing Li, Xiaojing He, Lingyan Jian
Clinical Therapeutics.2021;[Epub]     CrossRef
Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
Lucie Jiraskova, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud, Lukas Cerveny
Cancers.2019; 11(11): 1621.     CrossRef
Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
Antonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, Ruth Vera, Vega Iranzo, Inmaculada Ales, Sara Arévalo, Aleydis Pisa, Marta Martín, Antonieta Salud, Esther Falcó, Alberto Sáenz, José Luis Manzano Mozo, Gema Pulido, Joaquina Martínez Galán, Roberto
European Journal of Cancer.2017; 75: 73.     CrossRef
New targeted therapies in pancreatic cancer
Andrada Seicean
World Journal of Gastroenterology.2015; 21(20): 6127.     CrossRef